Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT05424978
Recruiting Observational

Application of Standardized Green Channel Treatment System for Ischemic Stroke in Xi 'an

NCT05424978 · tracked via the Priya Life Science China tracker
Sponsor
Xi'an No.3 Hospital
Phase
Observational
Started
2022-06-01
Last updated
2024-01-26

Condition(s) studied

Acute Ischemic StrokeThrombolysisEndovascular Treatment

Investigational drug(s) / intervention(s)

Standardized green channel treatment methods for stroke

Standardized green channel treatment methods for stroke: The measures include six measures: timely triage by triage desk nurses; Rapid evaluation by emergency room physician; If stroke is suspected, the green channel for nosocomial stroke should be activated immediately. Stroke greenway doctors and stroke nurses accompanied patients to complete CT examination; Intravenous thrombolysis in emergency rooms or CT rooms; Suspected macrovascular disease, if the onset time is less than 6 hours, quickly go to the catheter room for intravascular treatment; If the onset time was more than 6 hours, multi-mode imaging was used to quickly evaluate the ischemic penumbra and vascular occlusion, and then the patients were sent to the catheter room for intravascular treatment as soon as possible.

Study summary

Objective: To observe the practical application of the standardized green channel treatment system for stroke in Xi 'an in the real world. Methods: Clinical data and information of patients with acute ischemic stroke who received standardized green channel treatment for stroke were collected, and a multicenter observational clinical study was carried out in the real world to evaluate the prognosis, mortality, incidence of asymptomatic and symptomatic cerebral hemorrhage, incidence of pneumonia, and recurrence rate of stroke after 90 days.

Eligibility

Sex
ALL
Min age
18 Years
Max age
100 Years
Healthy volunteers
No
Inclusion Criteria: * 18 years old; * Consistent with the diagnosis of acute ischemic stroke; * 24 hours from onset to enrollment; * Informed consent Exclusion Criteria: * Patients who refuse to receive intravenous thrombolysis or intravascular intervention (including intravascular mechanical thrombolysis and arterial thrombolysis); * Stroke patients caused by brain tumor, brain trauma and blood diseases; * Those with a history of stroke and sequelae affecting the outcome assessment, namely, mRS 2 points before the onset of this stroke; * Combined with claudication osteoarthritis rheumatoid arthritis gout arthritis and other limb dysfunction and affect the neurological function examination; * Patients with severe hepatic and renal insufficiency (Note: Hepatic insufficiency refers to ALT or AST values greater than 2 times the upper normal limit; Renal insufficiency refers to blood creatinine value greater than 2 times the normal upper limit); * Suffering from other serious life-threatening diseases with an expected survival time of less than 3 months; * Other diseases that limit neurological function evaluation or affect patient follow-up; * A woman planning to be pregnant or breastfeeding; * Currently participating in other clinical trials; * Refuse to participate in the registration of investigators

Primary outcome measure(s)

  • Rate of function independent — 90 days after onset
    Rate of modified Rankin Scale(mRS) score less than 3 at 90 days

Trial sites (1)

FacilityCityRegionStatus
Xi 'an No.3 Hospital Xi'an Shaanxi Recruiting

More Xi'an No.3 Hospital trials in China

A New Parameter Derived From DSA to Evaluate Cerebral Perfusion Recruiting
Efficacy and Safety of Head Acupuncture After Mechanical Thrombectomy for Acute Ischemic Stroke Recruiting
Efficacy of Acupuncture for the Treatment of Parkinson's Disease Related Constipation Recruiting
Allogeneic UCB-derived, Dual-targeting BCMA/CD19 CAR-T for Relapsed/Refractory Multiple Myeloma Recruiting

Other trials for the same condition

RK-4 Intracalvariosseous Injection in Treatment of Acute Large Hemispheric Infarction Starting soon
Recombinant Human Prourokinase for Acute Ischemic Stroke in the Extended Window Selected by CT-Based Artificial Intelligence Starting soon
Sublingual Edaravone Dexborneol for Inter-hospital Transfer Acute Ischemic Stroke (SLEDAIS) Starting soon
Radial Versus Femoral Access For Thrombectomy in Patients With Acute Basilar Artery Occlusion Recruiting
Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05424978 on ClinicalTrials.gov ↗ ← All trials in China